Over the past twenty years, nuclear imaging has arguably had more impact on oncology
than any other field of medicine, particularly due to the ability of nuclear imaging to provide …

Molecular imaging is one of the fastest growing areas of medical imaging. Positron emission
tomography (PET) has been widely used in the clinical management of patients with cancer …

Molecular imaging is the visualization, characterization, and measurement of biological
processes at the molecular and cellular levels in a living system. At present, positron …

Over the past two decades, nuclear imaging has transformed cancer care. Positron emission
tomography (PET) and single photon emission computed tomography (SPECT) can provide …

Biochemical and molecular imaging of cancer using positron emission tomography (PET)
plays an increasing role in the care of cancer patients. Most clinical work to date uses the …

This chapter contains sections titled: What is Positron Emission Tomography?
Radiochemistry Considerations Pharmacological Objectives in Oncology Imaging Studies …

In oncology, biomarker research aimed to provide insights on cancer biology via positron
emission tomography (PET) and single photon emission tomography (SPECT) imaging has …

Currently, fluorine-18 labeled fluorodeoxyglucose (FDG), a glucose analogue, is the most
commonly used imaging agent for positron emission tomography (PET) in cancer patients …

Although 18 F-fluorodeoxyglucose (18 F-FDG) is still the most widely used positron emission
tomography (PET) radiotracer, there are a few well-known limitations to its use. The last …

The tumor-seeking agent most widely used in positron emission tomography (PET) is 2-18 F-
fluorodeoxy-d-glucose (FDG). The clinical usefulness of FDG PET has already been proved …